glp 1 maintenance dose after weight loss discontinuation of GLP-1 therapies what is considered a maintenance

Over the past several years, glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide have emerged as breakthrough therapies in the fight against obesity and related metabolic disorders

These new vials not only help us meet the high demand for our obesity medicine, but also broaden access for patients seeking a safe and effective treatment option, Patrik Jonsson, president of Lilly Cardiometabolic Health and Lilly USA, said in a statement

Klarity Health offers online weight loss treatment and works with many insurance plans

A 2022 study published in Diabetes, Obesity and Metabolism found that adults over 50 achieved clinically significant weight loss on semaglutide, with cardiovascular and metabolic risk reductions comparable to younger cohorts, though the authors noted the importance of individualized monitoring protocols for older patients given the higher baseline prevalence of comorbidities

This is due to the medications dual action: it mimics the GLP-1 hormone to signal fullness to the brain while simultaneously slowing down gastric emptying

Understanding compounding standards, provider qualifications, and how genetic predispositions in key peptide pathways may influence your response helps you engage more effectively with your healthcare team and set realistic expectations